A PATIENT-REPORTED OUTCOME MEASURE FOR SYMPTOMS AND SYMPTOM BURDEN OF ACUTE MYELOID LEUKEMIA (AML) AND MYELODYSPLASTIC SYNDROME (MDS).

被引：0
|
作者：
Williams, Loretta A. [1 ]
Gonzalez, Araceli Garcia [1 ]
Cortes, Jorge E. [1 ]
Garcia-Manero, Guillermo [1 ]
Mendoza, Tito R. [1 ]
Cleeland, Charles S. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
ONCOLOGY NURSING FORUM | 2016年 / 43卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
E-50
引用
收藏
页码：59 / 60
页数：2
相关论文
共 50 条
  • [41] A new patient-reported outcome measure for symptom benefit with chemotherapy: the Measure of Ovarian Symptoms and Treatment concerns (MOST)
    King, M. T.
    Stockler, M. R.
    Butow, P.
    O'Connell, R.
    Voysey, M.
    Oza, A. M.
    Gillies, K.
    Donovan, H. S.
    Mercieca-Bebber, R.
    Martyn, J.
    Sjoquist, K.
    Friedlander, M. L.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (09) : 20 - 20
  • [42] Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) following a diagnosis of breast cancer
    Padmanabhan, A.
    Block, A.
    Sait, S.
    Ford, L. A.
    O'Connor, T. L.
    Moysich, K. B.
    Baer, M. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [43] TRISOMY-14 IN ACUTE MYELOGENOUS LEUKEMIA (AML) AND MYELODYSPLASTIC SYNDROME (MDS)
    TOZE, CL
    BARNETT, MJ
    NAIMAN, SC
    HORSMAN, DE
    BLOOD, 1994, 84 (10) : A626 - A626
  • [44] Development and content validity of a hemodialysis symptom patient-reported outcome measure
    Flythe, Jennifer E.
    Dorough, Adeline
    Narendra, Julia H.
    Wingard, Rebecca L.
    Dalrymple, Lorien S.
    DeWalt, Darren A.
    QUALITY OF LIFE RESEARCH, 2019, 28 (01) : 253 - 265
  • [45] Validation of the psoriasis symptom inventory (PSI), a patient-reported outcome measure
    Martin, Mona L.
    Bushnell, Donald M.
    Gordon, Kenneth
    Huang, Xingyue
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 66 (04) : AB207 - AB207
  • [46] Development and content validity of a hemodialysis symptom patient-reported outcome measure
    Jennifer E. Flythe
    Adeline Dorough
    Julia H. Narendra
    Rebecca L. Wingard
    Lorien S. Dalrymple
    Darren A. DeWalt
    Quality of Life Research, 2019, 28 : 253 - 265
  • [47] Phase 1 study of CWP232291 in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
    Cortes, Jorge E.
    Faderl, Stefan
    Pagel, John
    Jung, Chul Won
    Yoon, Sung-Soo
    Koh, Youngil
    Pardanani, Animesh Dev
    Hauptschein, Robert S.
    Lee, Kyoung-June
    Lee, Je-Hwan
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [48] Prognostic factors for allogeneic stem cell transplantation (ASCT) for refractory acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS).
    Wong, R
    Shahjahan, M
    De Lima, M
    Anagnostopoulos, A
    Estey, E
    Champlin, R
    Andersson, B
    Khouri, I
    Giralt, S
    BLOOD, 2002, 100 (11) : 853A - 853A
  • [49] LOW-DOSE CYTOSINE-ARABINOSIDE IN THE TREATMENT OF ACUTE MYELOID-LEUKEMIA (AML) AND MYELODYSPLASTIC SYNDROME (MDS)
    WEH, HJ
    ZSCHABER, R
    HOSSFELD, DK
    BLUT, 1984, 48 (04): : 239 - 242
  • [50] Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)
    Amanda F. Cashen
    Ajit K. Shah
    Laura Todt
    Nicholas Fisher
    John DiPersio
    Cancer Chemotherapy and Pharmacology, 2008, 61 : 759 - 766
12345